Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

269.41 -2.05 (-0.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Amgen

< Previous 1 2
...
22 23 24 25 26 27 28 29 Next >
CNBC's Final Trades: Amgen, Marriot And Mastercard
On CNBC’s “Halftime Report Final Trades,” Car... 
Via Benzinga
Carter Worth Says This Stock Is 'So Bad That It Is Good'
On CNBC's "Options Action," Carter Worth... 
Via Benzinga
5 Stocks Getting Crushed - Are They Buying Opportunities?
Five dividend growth stocks that are down at least 20% from highs. 
Via Talk Markets
Danielle Shay Expects This Dow Laggard To Hit New Highs
On CNBC’s "Trading Nation 
Via Benzinga
Topics Stocks
Exposures US Equities
Clorox and Church & Dwight versus Amgen and Bristol-Myers Squibb
Base your stock investment decisions on fundamental values rather than short-term price activity. 
Via Talk Markets
Economic Reports Reflect Labor Shortages and Moderate Economic Growth
Stock futures are slightly lower as another large group of companies report earnings on Thursday. Starting with a surprise from AT&T (NYSE: T), the company is... 
Via Benzinga
Expert Ratings For Amgen
Amgen (NASDAQ:AMGN) has observed the following analyst ratings within the ... 
Via Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
AstraZeneca Pulls Plug On MCL-1 Cancer Drug Trial
AstraZeneca Plc (NASDAQ: AZN) has paused an active Phase 1 trial of AZD5991, a direct inhibitor of MCL-1, citing a potential safety issue. Two years ago, the FDA hit ... 
Via Benzinga
Exposures Product Safety
3 Biopharma Stocks To Watch Following Johnson & Johnson's Earnings Beat
Johnson & Johnson (NYSE:JNJ) shares are higher Tuesday fo... 
Via Benzinga
Esperion Chops 40% Workforce As Launch Of Cholesterol Medication Falters
Esperion Therapeutics Inc's (NASDAQ: ESPR) cholesterol drug marketing strategy has soured badly, as it has been struggling to sell its heart disease pill for more than a... 
Via Benzinga
Crispr: A Fallen Angel In Gene Editing
As with most promising biotech companies, investors bid their prices up for CRSP based on its potential for early profits. When the payoff didn't occur on schedule, investors bailed out. Once it... 
Via Talk Markets
How to Find Stocks on Sale in 2021
Despite the major stock indexes trading not far off their highs, some stocks have sold off and are now trading near their 52-week lows. Could there be some deals among those that are being discarded by... 
Via Talk Markets
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:... 
Via Benzinga
Exposures COVID-19
3 High-Yielding Dividend Stocks Trading Near Their 52-Week Lows
They may not be growth machines, but these stocks can generate a whole lot of dividend income for you. 
Via The Motley Fool
Debt Ceiling Agreement Helps Benchmarks Win 3 Straight
Better-than-expected jobless claims data for the week also boosted sentiment, with reopening and tech stocks leading the charge. 
Via Talk Markets
Amgen Highlights Lumakras Combination Data From Solid Tumor Trials
Amgen Inc (NASDAQ: AMGN) announced new combination study results from the Phase 1b CodeBreaK 101 study of Lumakras (sotorasib) for KRAS G12C-mutated... 
Via Benzinga
Amgen, Neumora Collaborate On Precision Therapies for Brain Diseases
Amgen Inc (NASDAQ: AMGN) and Neumora Therapeutics Inc have announced a strategic collaboration to advance neuroscience discovery, development, and... 
Via Benzinga
11 Dividend Contenders For Growth And Income
Despite the general high valuation of the overall market, these research candidates are currently sound and attractive. 
Via Talk Markets
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc... 
Via Benzinga
Biohaven Surges To Record High As Kardashian-Backed Migraine Drug Outperforms — Again
This company sells a migraine medicine backed by Khloe Kardashian. 
Via Investor's Business Daily
Amgen's Repatha Scores FDA Nod For Pediatric Patients Over 10 Years With Inherited Heart Disease
The FDA has approved Amgen Inc's (NASDAQ: AMGN) Repatha (evolocumab) as an adjunct for pediatric patients aged 10 years and older with heterozygous familial... 
Via Benzinga
Exposures Product Safety
Acceleron In Advanced $11B Buyout Talks: Bloomberg
Frothy rumors about possible M&A discussions at Acceleron Pharma Inc (NASDAQ: XLRN) were capped with a Bloomberg report asserting that the Company is... 
Via Benzinga
Where to Invest $100 Right Now
These choices may surprise you. 
Via The Motley Fool
Why Verastem Stock Spiked Today
A clinical collaboration with biotech titan Amgen briefly lit a fire underneath Verastem's shares today. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021
Upgrades Barclays upgraded the previous rating for Warner Music Group Corp (NASDAQ: 
Via Benzinga
Why Mirati Therapeutics Is A Dangerous Rival To Amgen In Colon Cancer
Mirati Therapeutics easily beat Amgen's test results in colon cancer. 
Via Investor's Business Daily
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics... 
Via Benzinga
Exposures COVID-19
Penny Biotech Stocks: 8 Things for Verastem Investors to Know as VSTM Stock Shoots Higher
Verastem (VSTM) stock is on the rise Monday morning following an announcement from the company concerning a deal with Amgen (AMGN). 
Via InvestorPlace
< Previous 1 2
...
22 23 24 25 26 27 28 29 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.